BeiGene (BGNE) Updates on BGB-A317 Phase 1; Seven Treatment-Related SAEs Noted
Tweet Send to a Friend
BeiGene, Ltd. (Nasdaq: BGNE) presented updated clinical data from an ongoing Phase I study of anti-PD-1 antibody BGB-A317 in patients ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
